Global EPO Biomarkers Market Research and Forecast 2018-2023
Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers Market are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Erythropoietin alfa is used to treat anemia and cancer cells and it increases the count of red blood cells in the body. Erythropoietin is mostly administered as an alternative to iron supplements. Moreover, the erythropoietin biomarkers are used to treat end-stage renal diseases (ESRD), and anemia induced from multiple myeloma, cancer, and AIDS associated anemia.
Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.
The EPO Biomarkers Market can be segmented on the basis of biomarker type, applications, and end users. Based on biomarker type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoietin alfa. Based on application, the market is bifurcated into end-stage renal disorder, cancers, rheumatoid arthritis, AIDS, myelodysplastic syndrome, neurology, hematology, and others (anaemia of chronic inflammatory syndromes). Based on end users, the market is segmented into diagnostic centers, ambulatory care and surgical centers, and hospitals. Among biomarker type, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer.
The global EPO biomarkers market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global EPO biomarkers market, followed by Europe. This is mainly owing to the developed healthcare infrastructure in the region. Moreover, the systematic initiatives taken by the government in the research and development activities is one of the major factors contributing in the growth of the EPO biomarkers market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are low cost of treatment therapy and increasing incidence rate of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh.
Some of the key players operating in the global EPO biomarkers market are Siemens AG, Thermo Fisher Scientific, Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Merck KGaA, LG Lifesciences Pvt Ltd, Amgen Inc., F. Hoffmann-LA Roche Ltd, and Agilent Technologies, Inc., among others. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance, in January 9, 2017, the Amgen Inc. has signed an agreement with DaVita Inc., a US-based healthcare solution provider. According to the agreement, the Amgen Inc. will supply DaVita’s EPOGEN (epoetin alfa) and Aranesp (darbepoetin alfa) in the U.S. and Puerto Rico.
RESEARCH METHODOLOGY
The market study of EPO biomarkers market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
MARKET SEGMENTATION:
Global EPO biomarkers market is segmented on the basis of regional outlook and following segments:
1. Global EPO Biomarkers Market Research and Analysis, By Biomarker Type
2. Global EPO Biomarkers Market Research and Analysis, By Applications
3. Global EPO Biomarkers Market Research and Analysis, By End Users
4. Global EPO Biomarkers Market Research and Analysis, By Region
THE REPORT COVERS:
Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.
The EPO Biomarkers Market can be segmented on the basis of biomarker type, applications, and end users. Based on biomarker type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoietin alfa. Based on application, the market is bifurcated into end-stage renal disorder, cancers, rheumatoid arthritis, AIDS, myelodysplastic syndrome, neurology, hematology, and others (anaemia of chronic inflammatory syndromes). Based on end users, the market is segmented into diagnostic centers, ambulatory care and surgical centers, and hospitals. Among biomarker type, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer.
The global EPO biomarkers market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global EPO biomarkers market, followed by Europe. This is mainly owing to the developed healthcare infrastructure in the region. Moreover, the systematic initiatives taken by the government in the research and development activities is one of the major factors contributing in the growth of the EPO biomarkers market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are low cost of treatment therapy and increasing incidence rate of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh.
Some of the key players operating in the global EPO biomarkers market are Siemens AG, Thermo Fisher Scientific, Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Merck KGaA, LG Lifesciences Pvt Ltd, Amgen Inc., F. Hoffmann-LA Roche Ltd, and Agilent Technologies, Inc., among others. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance, in January 9, 2017, the Amgen Inc. has signed an agreement with DaVita Inc., a US-based healthcare solution provider. According to the agreement, the Amgen Inc. will supply DaVita’s EPOGEN (epoetin alfa) and Aranesp (darbepoetin alfa) in the U.S. and Puerto Rico.
RESEARCH METHODOLOGY
The market study of EPO biomarkers market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
- Financial reports of companies involved in the market
- Authentic public databases such as WHO, World Anti-Doping Agency (WADA), and Centers for Disease Control and Prevention (CDC), among others.
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalogue
- Supplier Websites such as Alibaba, amazon for pricing analysis
MARKET SEGMENTATION:
Global EPO biomarkers market is segmented on the basis of regional outlook and following segments:
1. Global EPO Biomarkers Market Research and Analysis, By Biomarker Type
2. Global EPO Biomarkers Market Research and Analysis, By Applications
3. Global EPO Biomarkers Market Research and Analysis, By End Users
4. Global EPO Biomarkers Market Research and Analysis, By Region
THE REPORT COVERS:
- Comprehensive research methodology of global EPO biomarkers market
- This report also includes detailed and extensive market overview with key analyst insights
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
- Analysis of regional regulations and other government policies impacting the global EPO biomarkers market
- Insights about market determinants which are stimulating the global EPO biomarkers market
- Detailed and extensive market segments with regional distribution of forecasted revenues
- Extensive profiles and recent developments of market players
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING INCIDENCE OF CANCERS AND RENAL DISORDERS
3.1.2. SEDENTARY LIFESTYLE AND FAULTY DIETARY HABITS
3.1.3. INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES SUCH AS DIABETES
3.1.4. UPCOMING PATENT EXPIRATION OF EPO BIOMARKERS
3.2. RESTRAINTS
3.2.1. LESS OF QUALITY CONTROL TESTING LABORATORIES IN EMERGING ECONOMIES
3.3. OPPORTUNITIES
3.3.1. FAVORABLE HEALTHCARE REGULATIONS IN EMERGED ECONOMIES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL EPO BIOMARKER MARKET, BY BIOMARKER TYPE
4.1.1. ERYTHROPOIETIN ALFA
4.1.2. ERYTHROPOIETIN BETA
4.1.3. ERYTHROPOIETIN ZETA
4.1.4. ERYTHROPOIETIN THETA
4.1.5. RECOMBINANT HUMAN ERYTHROPOIETIN
4.1.6. DARBEPOIETIN ALFA
4.2. GLOBAL EPO BIOMARKER MARKET, BY APPLICATIONS
4.2.1. END-STAGE RENAL DISORDER
4.2.2. CANCERS
4.2.3. RHEUMATOID ARTHRITIS
4.2.4. AIDS
4.2.5. MYELODYSPLASTIC SYNDROME
4.2.6. NEUROLOGY
4.2.7. HEMATOLOGY
4.2.8. OTHERS (ANAEMIA OF CHRONIC INFLAMMATORY SYNDROMES)
4.3. GLOBAL EPO BIOMARKER MARKET, BY END USERS
4.3.1. DIAGNOSTIC CENTERS
4.3.2. AMBULATORY CARE AND SURGICAL CENTERS
4.3.3. HOSPITALS
CHAPTER 5. COMPETITIVE LANDSCAPE
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. 3SBIO GROUP
7.2. AGILENT TECHNOLOGIES, INC.
7.3. AMGEN INC.
7.4. BIOAGILYTIX LABS
7.5. BIOCON
7.6. BIO-RAD LABORATORIES, INC.
7.7. EVE TECHNOLOGIES
7.8. F. HOFFMANN-LA ROCHE LTD
7.9. GALENICA AG
7.10. GENSCRIPT
7.11. GLAXOSMITHKLINE PLC.
7.12. INTAS PHARMACEUTICALS LTD.
7.13. JOHNSON & JOHNSON SERVICES, INC.
7.14. KYOWA HAKKO KIRIN CO., LTD.
7.15. LG LIFESCIENCES PVT LTD
7.16. MERCK KGAA
7.17. MYRIAD RBM
7.18. NOVARTIS AG
7.19. PACIFIC BIOMARKERS
7.20. PFIZER INC.
7.21. SANDOZ INTERNATIONAL GMBH
7.22. SHANDONG KEXING
7.23. SIEMENS AG
7.24. THERMO FISHER SCIENTIFIC
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING INCIDENCE OF CANCERS AND RENAL DISORDERS
3.1.2. SEDENTARY LIFESTYLE AND FAULTY DIETARY HABITS
3.1.3. INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES SUCH AS DIABETES
3.1.4. UPCOMING PATENT EXPIRATION OF EPO BIOMARKERS
3.2. RESTRAINTS
3.2.1. LESS OF QUALITY CONTROL TESTING LABORATORIES IN EMERGING ECONOMIES
3.3. OPPORTUNITIES
3.3.1. FAVORABLE HEALTHCARE REGULATIONS IN EMERGED ECONOMIES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL EPO BIOMARKER MARKET, BY BIOMARKER TYPE
4.1.1. ERYTHROPOIETIN ALFA
4.1.2. ERYTHROPOIETIN BETA
4.1.3. ERYTHROPOIETIN ZETA
4.1.4. ERYTHROPOIETIN THETA
4.1.5. RECOMBINANT HUMAN ERYTHROPOIETIN
4.1.6. DARBEPOIETIN ALFA
4.2. GLOBAL EPO BIOMARKER MARKET, BY APPLICATIONS
4.2.1. END-STAGE RENAL DISORDER
4.2.2. CANCERS
4.2.3. RHEUMATOID ARTHRITIS
4.2.4. AIDS
4.2.5. MYELODYSPLASTIC SYNDROME
4.2.6. NEUROLOGY
4.2.7. HEMATOLOGY
4.2.8. OTHERS (ANAEMIA OF CHRONIC INFLAMMATORY SYNDROMES)
4.3. GLOBAL EPO BIOMARKER MARKET, BY END USERS
4.3.1. DIAGNOSTIC CENTERS
4.3.2. AMBULATORY CARE AND SURGICAL CENTERS
4.3.3. HOSPITALS
CHAPTER 5. COMPETITIVE LANDSCAPE
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. 3SBIO GROUP
7.2. AGILENT TECHNOLOGIES, INC.
7.3. AMGEN INC.
7.4. BIOAGILYTIX LABS
7.5. BIOCON
7.6. BIO-RAD LABORATORIES, INC.
7.7. EVE TECHNOLOGIES
7.8. F. HOFFMANN-LA ROCHE LTD
7.9. GALENICA AG
7.10. GENSCRIPT
7.11. GLAXOSMITHKLINE PLC.
7.12. INTAS PHARMACEUTICALS LTD.
7.13. JOHNSON & JOHNSON SERVICES, INC.
7.14. KYOWA HAKKO KIRIN CO., LTD.
7.15. LG LIFESCIENCES PVT LTD
7.16. MERCK KGAA
7.17. MYRIAD RBM
7.18. NOVARTIS AG
7.19. PACIFIC BIOMARKERS
7.20. PFIZER INC.
7.21. SANDOZ INTERNATIONAL GMBH
7.22. SHANDONG KEXING
7.23. SIEMENS AG
7.24. THERMO FISHER SCIENTIFIC
LIST OF TABLES
TABLE 1 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS, BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL ERYTHROPOIETIN ALFA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ERYTHROPOIETIN BETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL ERYTHROPOIETIN ZETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL ERYTHROPOIETIN THETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL RECOMBINANT HUMAN ERYTHROPOIETIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL DARBEPOIETIN ALFA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL END-STAGE RENAL DISORDER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL CANCERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL RHEUMATOID ARTHRITIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL AIDS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL MYELODYSPLASTIC SYNDROME MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL NEUROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 GLOBAL HEMATOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 16 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 17 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USERS, 2017-2023 ($ MILLION)
TABLE 18 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 19 GLOBAL AMBULATORY CARE AND SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 20 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 21 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE 22 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 23 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 24 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 25 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 26 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 27 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 28 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 29 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 30 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 31 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 32 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 33 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 34 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 35 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 36 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 1 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS, BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL ERYTHROPOIETIN ALFA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ERYTHROPOIETIN BETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL ERYTHROPOIETIN ZETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL ERYTHROPOIETIN THETA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL RECOMBINANT HUMAN ERYTHROPOIETIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL DARBEPOIETIN ALFA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL END-STAGE RENAL DISORDER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL CANCERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL RHEUMATOID ARTHRITIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL AIDS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL MYELODYSPLASTIC SYNDROME MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL NEUROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 GLOBAL HEMATOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 16 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 17 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USERS, 2017-2023 ($ MILLION)
TABLE 18 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 19 GLOBAL AMBULATORY CARE AND SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 20 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 21 GLOBAL EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE 22 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 23 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 24 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 25 NORTH AMERICAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 26 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 27 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 28 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 29 EUROPEAN EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 30 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 31 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 32 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 33 APAC EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 34 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
TABLE 35 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
TABLE 36 ROW EPO BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL EPO BIOMARKER MARKET SHARE BY BIOMARKER TYPE, 2017 VS 2023 (%)
FIGURE 2 GLOBAL EPO BIOMARKER MARKET SHARE BY APPLICATIONS, 2017 VS 2023 (%)
FIGURE 3 GLOBAL EPO BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA EPO BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 14 JAPAN EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 ROAPAC EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 REST OF THE WORLD EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
7.1. 3SBIO GROUP
7.2. AGILENT TECHNOLOGIES, INC.
7.3. AMGEN INC.
7.4. BIOAGILYTIX LABS
7.5. BIOCON
7.6. BIO-RAD LABORATORIES, INC.
7.7. EVE TECHNOLOGIES
7.8. F. HOFFMANN-LA ROCHE LTD
7.9. GALENICA AG
7.10. GENSCRIPT
7.11. GLAXOSMITHKLINE PLC.
7.12. INTAS PHARMACEUTICALS LTD.
7.13. JOHNSON & JOHNSON SERVICES, INC.
7.14. KYOWA HAKKO KIRIN CO., LTD.
7.15. LG LIFESCIENCES PVT LTD
7.16. MERCK KGAA
7.17. MYRIAD RBM
7.18. NOVARTIS AG
7.19. PACIFIC BIOMARKERS
7.20. PFIZER INC.
7.21. SANDOZ INTERNATIONAL GMBH
7.22. SHANDONG KEXING
7.23. SIEMENS AG
7.24. THERMO FISHER SCIENTIFIC
FIGURE 1 GLOBAL EPO BIOMARKER MARKET SHARE BY BIOMARKER TYPE, 2017 VS 2023 (%)
FIGURE 2 GLOBAL EPO BIOMARKER MARKET SHARE BY APPLICATIONS, 2017 VS 2023 (%)
FIGURE 3 GLOBAL EPO BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA EPO BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 14 JAPAN EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 ROAPAC EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 REST OF THE WORLD EPO BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
7.1. 3SBIO GROUP
7.2. AGILENT TECHNOLOGIES, INC.
7.3. AMGEN INC.
7.4. BIOAGILYTIX LABS
7.5. BIOCON
7.6. BIO-RAD LABORATORIES, INC.
7.7. EVE TECHNOLOGIES
7.8. F. HOFFMANN-LA ROCHE LTD
7.9. GALENICA AG
7.10. GENSCRIPT
7.11. GLAXOSMITHKLINE PLC.
7.12. INTAS PHARMACEUTICALS LTD.
7.13. JOHNSON & JOHNSON SERVICES, INC.
7.14. KYOWA HAKKO KIRIN CO., LTD.
7.15. LG LIFESCIENCES PVT LTD
7.16. MERCK KGAA
7.17. MYRIAD RBM
7.18. NOVARTIS AG
7.19. PACIFIC BIOMARKERS
7.20. PFIZER INC.
7.21. SANDOZ INTERNATIONAL GMBH
7.22. SHANDONG KEXING
7.23. SIEMENS AG
7.24. THERMO FISHER SCIENTIFIC
